Nuvalent
Yahoo Finance • 2 months ago
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical tri... Full story
Yahoo Finance • 2 months ago
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceuti... Full story
Yahoo Finance • 9 months ago
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story
Yahoo Finance • 2 years ago
12 Best Small-Cap Healthcare Stocks To Buy Now
In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will... Full story
